Archiv
Archiv anzeigen:
bis


An Emerging Treatment for Acute Graft-Versus-Host Disease

Michael E. Williams, MD, ScM reviewing Zeiser R et al. N Engl J Med 2020 Apr 22

Ruxolitinib was superior to investigator's choice of treatment for patients with glucocorticoid-refractory GVHD following allogeneic stem cell transplantation.


The Impact of Cytokine Suppression on Anemia

Brady L. Stein, MD, MHS reviewing Vallurupalli M et al. Ann Intern Med 2020 Apr 21

Interleukin-1β inhibition reduced incident anemia and improved hemoglobin levels in patients with baseline anemia.


Long-Term Outcomes of EUS-Guided Hepaticogastrostomy

Douglas G. Adler, MD, FACG, AGAF, FASGE reviewing Nakai Y et al. Gastrointest Endosc 2020 Apr 9

Success rates were high, but so were adverse event rates.


The Intelligent Knife: New Approach to Cancer Surgery

Anthony L. Komaroff, MD reviewing Tzafetas M et al. Proc Natl Acad Sci U S A 2020 Mar 31

Will point-of-care mass spectrometry be the next breakthrough in cancer resection?


Adjuvant Chemotherapy for Small Breast Cancers?

William J. Gradishar, MD reviewing Ma SJ et al. JAMA Netw Open 2020 Apr 1

Adding chemotherapy to endocrine therapy did not improve survival for patients with tumors less than 8 mm in size.


Lusutrombopag for Severe Thrombocytopenia in Patients with Hepatocellular Carcinoma

Atif Zaman, MD, MPH reviewing Alkhouri N et al. Clin Gastroenterol Hepatol 2020 Mar 20

Lusutrombopag was safe and effective in an integrated analysis of two phase III trials.


Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancer

Robert Dreicer, MD, MS, MACP, FASCO reviewing Phillips R et al. JAMA Oncol 2020 Mar 26

Disease progression at 6 months was significantly reduced with radiotherapy versus observation.


Coagulopathy Associated with COVID-19

Brady L. Stein, MD, MHS reviewing Thachil J et al. J Thromb Haemost 2020 Mar 25

An international panel provides guidance on prognostic variables and management strategies for COVID-19–associated coagulopathy.


Apixaban vs. Dalteparin for Cancer-Associated Venous Thromboembolism

Brady L. Stein, MD, MHS reviewing Agnelli G et al. N Engl J Med 2020 Mar 29, Lee AYY. N Engl J Med 2020 Mar 29

Rates of recurrent VTE were noninferior with oral apixaban compared with subcutaneous dalteparin, and rates of major bleeding were similar.


Luspatercept for Transfusion-Dependent β-Thalassemia

Brady L. Stein, MD, MHS reviewing Cappellini MD et al. N Engl J Med 2020 Mar 26

Luspatercept reduced transfusion burden compared with placebo.


Archiv
Seite von 93